IndustryCompany release

Milestone cuts costs by about 30% as CARDAMYST posts $1.0M third-quarter sales

🇺🇸 Milestone Pharmaceuticals Inc. (MIST) · Fri 13 Nov 2026

The US company says payer coverage for its PSVT nasal spray has reached about two-thirds of covered lives, and its cash runway now extends into late 2028.

Milestone Pharmaceuticals reported third-quarter results on 13 November 2026, with net revenue of $1.0 million from CARDAMYST (etripamil nasal spray). The product is approved by the US Food and Drug Administration for paroxysmal supraventricular tachycardia (PSVT). The company said sales were up 73% on the second quarter.

Commercial payer coverage has widened to about two-thirds of covered lives, according to the company. Milestone did not give a breakdown by payer in the information available to VigiEye.

Alongside the results, Milestone announced a cost-reduction plan that it says cuts operating costs by about 30% and extends its cash runway into late 2028. The plan brings its sales force of around 45 people in-house and reduces the headquarters workforce. The company's chief financial officer and chief medical officer are also leaving.

Milestone has also amended its convertible note held by RTW so that payment-in-kind (PIK) interest continues until March 2029. PIK interest is added to the principal rather than paid in cash.

In its pipeline, the Phase 3 ReVeRA-301 trial of etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) remains on schedule. Topline data are expected in the second half of 2028.

What it means for your team

  • Market access teams can note that commercial coverage for CARDAMYST now reaches about two-thirds of covered lives, although the revenue base is still small at $1.0M.
  • The departure of the CFO and CMO, together with the in-house sales force, may change Milestone's contacts for medical and commercial matters.
  • For teams tracking the AFib-RVR programme, the timeline is unchanged: ReVeRA-301 topline data are still expected in the second half of 2028.

Company's press release (SEC filing): Milestone Pharmaceuticals Inc. ↗

Article written by VigiEye from the official source (Milestone Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →